En español



Asian American Pacific Islander Researchers and Scholars Workgroup (AAPI)

Mission and Goals

The AAPI Working Group fosters interdisciplinary and translational research focusing on the drug use and abuse and related health conditions affecting AAPIs. It is also committed to increasing the participation and development of AAPI scientists in the fields of drug use, abuse and related research, and to increasing collaborative activities among research scientists and AAPI communities.

Major Highlights and Accomplishments

The AAPI Workgroup has identified and engaged a large group of NIH researchers representing a multitude of disciplines interested in interdisciplinary and translational research as it affects AAPI communities.

The Workgroup members are working with its core of researchers in order to grow and expand the membership, mentoring, and scientific capacity.

  • NIDA Asian American/Pacific Islander Researchers & Scholars Workgroup Meeting
    “Advancing AAPI Drug Abuse/Mental Health Prevention Sciences and Treatment: Transdisciplinary Frameworks”    June 2-3, 2010, Alexandria VA
    This meeting focused on mentor training and development and was available to AAPI researchers interested in mentorship or a career in substance abuse research focused on AAPI-relevant issues. 26 mentees attended.
  • Diversity Alumni Meeting, Joint Meeting of NIDA’s Racial/Ethnic Minority Workgroups & NIDA AAPI Workgroup Meeting
    November 7-8, 2011, Bethesda, MD
  • AAPI Early Career Investigator Symposium, affiliated with NIDA Mini-convention, held on November 11, 2011, Washington DC
    The AAPI Workgroup sponsored 6 travel awards for emerging scientists from different minority groups who attended and presented their research at the symposium. The program accentuated the workgroup’s mission in coaching and training of socially and economically disadvantaged minority junior investigators. It permitted the junior investigators to interact with AAPI investigators. The AAPI Mentoring and Training session consisted of topics on scientific writing, benefit of serving NIH study sections and an orientation for junior investigators to attend NIDA Grant Workshop.
  • The AAPI Workgroup provided travel awards for emerging scientists to attend and participate at the 2012 Society on Neuroimmune Pharmacology (SNIP) conference, April 25-28 in Honolulu, Hawaii.  SNIP is one of the scientific forums to nurture the early careers of this special population of young investigators.

Upcoming Events

  • 2012 College on Problems of Drug Dependence (CPDD) Meeting, June 9-14 in Palm Springs, CA
    The AAPI Workgroup is providing 9 travel awards for emerging scientists to attend and present posters at the 2012 CPDD international conference. On behalf of NIDA Special Population Office, it will conduct an on-site training/mentoring program in this conference for NIDA racial ethnic minority early stage investigators.  It has also collaborated with NIDA’s International Office in sponsoring international scientists.
  • 2012 Health Disparity Conference, July 11-13 in Fort Worth, Texas
    The AAPI Workgroup sponsors a workshop in this conference entitled “Tobacco Smoking, HIV/AIDS and Cancer in Health Disparity Population”.  It will introduce NIDA and NIDA’s science to the audience and the community and will present program priorities, research opportunities at NIDA and NIH.

Resources and Links

Workgroup Roster

  • Ana Anders, LICSW
    Senior Advisor, Special Populations Office
    National Institute on Drug Abuse/NIH
    6001 Executive Boulevard, Room 4216, MSC 9567
    Bethesda, MD 20892-9567
    (301) 435-0919
    (301) 480-8179
  • Shilpa Buch, PhD
    Professor and Vice Chair for Research
    Dept of Pharmacology & Experimental Neuroscience
    University of Nebraska Medical Center
    985880 Nebraska Medical Center, DRC 8011
    Omaha, NE 68198-5880
    (402) 559-3165
    (402) 559-3744
  • Linda Chang, MD
    Professor, Department of Medicine
    University of Hawaii, John A. Burns School of Medicine
    The Queen's Medical Center
    Honolulu, HI 96813
    (808) 586-7467
    (808) 586-7486
  • Sulie L. Chang, PhD
    Professor, Seton Hall University
    Director, Institute of NeuroImmune Pharmacology
    400 South Orange Avenue
    South Orange, NJ 07079
    (973) 761-9456
    (973) 275-2489
  • Johnny J. He, PhD
    Associate Dean, Biomedical Education and Research;
    Professor, Cell Biology and Anatomy
    University of North Texas Health Science Center
    3500 Camp Bowie Boulevard
    Fort Worth, TX 76107
    (817) 735-2642
    (817) 738-0181
  • Yih-Ing Hser, PhD
    Professor and Center Director
    UCLA Center of Advancing Longitudinal Drug Abuse Research
    1640 South Sepulveda Boulevard, Suite 200
    Los Angeles, CA 90025
    (310) 267-5388
  • Anil Kumar, PhD
    Chair and Professor, School of Pharmacy
    University of Missouri-Kansas City, Division of Pharmacology
    2411 Holmes, M3-111
    Kansas City, MO 64108
    (816) 235-2415
    (816) 235-1776
  • Ming D. Li, PhD
    Professor, Psychiatry and Neurobehavioral Sciences
    University of Virginia School of Medicine
    1670 Discovery Drive, Suite 110
    Charlottesville, VA 22911
    (434) 243-0566
    (434) 973-7031
  • Yu “Woody” Lin, Ph.D.
    Program Director,
    Clinical Neuroscience Branch
    Division of Clinical Neuroscience and Behavioral Research
    National Institute on Drug Abuse
    6001 Executive Boulevard
    Bethesda, MD 20892-9555
    (301) 435-1318
  • Walter Ling, MD
    Professor of Psychiatry
    UCLA Integrated Substance Abuse Programs
    Director of Integrated Substance Abuse Programs
    11075 Santa Monica Boulevard, Suite 200
    Los Angeles,CA 90025
    (310) 267-5888
    (310) 312-0552
  • Rumi Kato Price, PhD
    Professor, Washington University School of Medicine
    Medical Box 8134
    660 South Euclid Avenue
    St Louis, MO 63110
    (314) 286-2282
    (314) 286-2285
  • Joseph T. Sakai, MD
    Assistant Professor, Division of Substance Dependence
    University of Colorado Denver, School of Medicine
    12469 East 17th Place, Building 400
    Aurora, CO 80045
    (303) 724-3182
    (303) 724-3178
  • Betty Tai, PhD
    Director, Center for the Clinical Trials Network
    National Institute on Drug Abuse/NIH
    6001 Executive Boulevard, Room 3120
    Bethesda, MD 20892-9557
    (301) 443-6697
    (301) 443-2317
  • Madhukar H. Trivedi, MD
    Professor of Psychiatry, University of Texas Southwestern Medical Center
    Director, Mood Disorders Research Program and Clinic
    5323 Harry Hines Boulevard
    Dallas, TX 75390
    (214) 648-0181
  • Gene-Jack Wang, MD
    Senior Scientist
    Brookhaven National Laboratory, Medical Department
    Building 490, PO Box 5000
    Upton, NY 11973-5000
    (631) 344-3608
  • Li-Tzy Wu, ScD
    Professor, Psychiatry and Behavioral Sciences
    Duke University Medical Center
    DUMC Box 3419
    Durham, NC 27710
    (919) 889-9369
    (919) 677-8480
  • Bryan K. Yamamoto, PhD
    Professor and Chairman
    University of Toledo College of Medicine, Department of Neurosciences
    Mail Stop #1007, 3000 Arlington Avenue
    Toledo, OH 43614-2598
    (419) 383-6115
    (419) 383-3008

This page was last updated April 2012

    Featured Publication

    Featured Publication

    Drugs, Brains, and Behavior - The Science of Addiction

    As a result of scientific research, we know that addiction is a disease that affects both brain and behavior.